A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Chronic Myeloid Leukaemia Clinical Trial

Official title:

A RETROSPECTIVE OBSERVATIONAL RESEARCH STUDY TO DESCRIBE THE REAL WORLD USE OF BOSUTINIB IN THE UK AND NETHERLANDS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02546375
• Other study ID #: B1871052
• Status: Completed
• Start date: July 15, 2015
• Est. completion date: January 16, 2017

Study information

• Verified date: September 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: January 16, 2017
• Est. primary completion date: January 16, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of Ph+ CML aged =18 years at bosutinib initiation.
• Prescribed bosutinib (irrespective of the phase of their disease) EITHER in normal clinical practice since it received marketing authorisation (27th March 2013) by the EMA11 OR via the compassionate use programme prior to marketing authorization.
• Where required, evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

• Prescribed bosutinib as part of an interventional clinical trial programme.
• Initiated on bosutinib less than 3 months prior to data collection taking place.

Related Conditions & MeSH terms

• Chronic Myeloid Leukaemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

Intervention

Drug:
• Bosutinib
Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)

Locations

Country	Name	City	State
United Kingdom	Royal Liverpool Hospital	Liverpool	Merseyside
United Kingdom	Hammersmith Hospital	London
United Kingdom	Nottingham University Hospital	Nottingham

Sponsors (2)

Lead Sponsor	Collaborator
Pfizer	pH Associates

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Cumulative Complete Haematological Response (CHR)	Haematological response used blood sample of the participants to evaluate response to treatment for CML. Based on the European LeukemiaNet (ELN) 2013 definition: CHR is defined as platelet count less than (<) 450*10^9 per liter, white blood cells count <10*10^9 per liter, no immature granulocytes and <5 percent (%) basophils on differential and a non-palpable spleen.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Partial Haematological Response (PHR)	Haematological response used blood sample of the participants to evaluate response to treatment for CML.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Complete Cytogenetic Response (CCyR)	Cytogenetic response (CyR) used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by chromosome banding analysis (CBA) or fluorescence in situ hybridisation (FISH). CCyR was indicated by absence of Philadelphia chromosome positive (Ph+) cells metaphases from FISH of blood interphase cell nuclei.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Minor Cytogenetic Response (MCyR)	CyR used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by CBA or FISH. MCyR was indicated by presence of 36-65% Ph+ cells from CBA of bone marrow metaphases.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Minimal Cytogenetic Response (mCyR)	CyR used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by CBA or FISH. mCyR was indicated by presence of 66-95% Ph+ cells from CBA of bone marrow metaphases.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Partial Cytogenetic Response (PCyR)	CyR used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by CBA or FISH. PCyR was indicated by presence of 1-35% Ph+ cells from CBA of bone marrow metaphases.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Complete Molecular Response 4.0 (MR4.0)	Molecular response used blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: Molecular response used breakpoint cluster region/Abelson (BCR-ABL1) transcript measured by real time quantitative polymerase chain reaction (RT-Q-PCR). Evaluation was expressed as percentage of ratio of BCR-ABL1 transcripts to ABL1 transcripts according to the international scale (IS) or the ratio of BCR/ABL1 transcripts to other internationally recognized control transcripts levels. MR4.0 was defined and recorded as detectable disease with <0.01% BCR-ABL1 transcripts on IS or undetectable disease in cDNA with greater than (>) 10,000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1 transcripts.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Complete Molecular Response 4.5 (MR4.5)	Molecular response used blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: Molecular response used breakpoint cluster region/Abelson (BCR-ABL1) transcript measured by real time quantitative polymerase chain reaction (RT-Q-PCR). Evaluation was expressed as percentage of ratio of BCR-ABL1 transcripts to ABL1 transcripts according to the international scale (IS) or the ratio of BCR/ABL1 transcripts to other internationally recognized control transcripts levels. MR4.5 was defined and recorded as detectable disease with <0.0032% BCR-ABL1 transcripts on IS or undetectable disease in cDNA with >32,000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1 transcripts.	Baseline up to 5.5 years
Primary	Percentage of Participants With Cumulative Major Molecular Response (MMR)/Molecular Response 3.0 (MR3.0)	Molecular response used blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: Molecular response used breakpoint cluster region/Abelson (BCR-ABL1) transcript measured by real time quantitative polymerase chain reaction (RT-Q-PCR). Evaluation was expressed as percentage of ratio of BCR-ABL1 transcripts to ABL1 transcripts according to the international scale (IS) or the ratio of BCR/ABL1 transcripts to other internationally recognized control transcripts levels. MMR was defined as a BCR-ABL1 to ABL1 less than or equal to (<=) 0.1% on the IS.	Baseline up to 5.5 years
Secondary	Percentage of Participants With Treatment Related Adverse Events (AEs)	Treatment-related AE was any untoward medical occurrence attributed to Bosutinib in a participant who received Bosutinib. Relatedness to Bosutinib was assessed by the investigator.	Baseline up to 5.5 years
Secondary	Percentage of Participants With Treatment Related Adverse Events (AEs) Greater Than or Equal to Grade 3	Treatment-related AE was any untoward medical occurrence attributed to Bosutinib in a participant who received Bosutinib. AE was assessed according to maximum severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Grade 1 =mild; Grade 2 =moderate; within normal limits, Grade 3 =severe or medically significant but not immediately life-threatening; Grade 4 =life-threatening or disabling; urgent intervention indicated; Grade 5 =death.	Baseline up to 5.5 years
Secondary	Progression-free Survival (PFS)	PFS was defined as the duration between initiation of Bosutinib therapy and date of progression estimated by the treating physician or death of participant (all causes combined). Progression was defined as change from chronic phase of CML (CP-CML) to accelerated phase of CML (AP-CML) or to blast crisis of CML (BC-CML). CP-CML is frequently asymptomatic and diagnosed with <10% blasts. Based on the ELN 2013 definition: AP-CML was defined by the presence of blast cells between 15-29% or blast cells plus promyelocytes >30%, with blasts <30% in blood or bone marrow, platelet count <100*10^9 or clonal chromosome abnormalities in Ph+ cells. BC-CML was defined as blasts in blood or bone marrow >=30%, extramedullary blast proliferation (excluding spleen), large foci or clusters of blasts in bone marrow biopsy. Participants who were alive at the date of last assessment were censored on the date of data collection.	Year 1, 2, 3
Secondary	Overall Survival (OS)	OS was defined as the duration from initiation of Bosutinib therapy to date of death (all causes combined). For participants who were alive or lost to follow-up (LTFU), overall survival was censored on the date of data collection or date LTFU, respectively.	From baseline up to 1 Year, baseline up to Year 2, baseline up to Year 3
Secondary	Percentage of Participants With Disease Progression	Progression was defined as change from CP-CML to AP-CML or to BC-CML. CP-CML is frequently asymptomatic and diagnosed with <10% blasts. Based on the ELN 2013 definition: AP-CML was defined by the presence of blast cells between 15-29% or blast cells plus promyelocytes >30%, with blasts <30% in blood or bone marrow, platelet count <100*10^9 or clonal chromosome abnormalities in Ph+ cells. BC-CML was defined as blasts in blood or bone marrow >=30%, extramedullary blast proliferation (excluding spleen), large foci or clusters of blasts in bone marrow biopsy.	Year 1, 2, 3
Secondary	Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy		Baseline up to 5.5 years
Secondary	Cross-Intolerance Between Bosutinib and Previous Therapy	Cross-intolerance was defined as percentage of participants who permanently discontinued bosutinib due to an adverse event which also resulted in discontinuation of a previous treatment (imatinib, dasatinib, nilotinib).	Baseline up to 5.5 years
Secondary	Mean Dose of Bosutinib at Initiation of Treatment		Baseline up to 5.5 years
Secondary	Relative Bosutinib Dose Intensity	Relative dose intensity was defined as the percentage of daily dose received over the expected daily dose of the study drug.	Baseline up to 5.5 years
Secondary	Duration of Bosutinib Therapy	The duration from initiation of Bosutinib therapy up to the end of Bosutinib therapy was reported in this outcome measure.	Baseline up to 5.5 years

External Links

•   To obtain contact information for a study center near you, click here.